US EditionPublished • loading... • Updated
GSK forecasts slower sales growth in 2026
- GSK forecast fiscal 2026 sales of 3%-5% and reported 2025 revenue rose 4% to £32.7 billion in the first full-year results under CEO Luke Miels.
- Specialty medicines drove growth, with sales up 17% to 13.5 billion, supported by 18% in RI&I and 11% in HIV, plus vaccine contributions including Shingrix and Arexvy, with China boosting sales.
- Soon after taking charge, Miels announced the $2.2 billion RAPT Therapeutics acquisition and flagged $40 billion US investment, as shares climbed near six percent on the London Stock Exchange.
- Because the US accounts for more than half of GSK's revenues, management said 2026 guidance considers agreed US price cuts and tariff exemptions.
- Management highlighted five major product approvals and strengthened pipeline focus on oncology and RI&I, emphasizing the company's UK commitment with 10,000 employees and around �1.5 billion in R&D spend, as Miels said, 'So we're heavily committed to the UK.
Insights by Ground AI
76 Articles
76 Articles
Stewart Reports Fourth Quarter and Full Year 2025 Results
Total revenues of $790.6 million ($794.4 million on an adjusted basis) compared to $665.9 million ($664.2 million on an adjusted basis) in the prior year quarterNet income of $36.3 million ($47.9 million on an adjusted basis) compared to net income…
InsideNoVA.com+12 Reposted by 12 other sources
GSK boosted by specialty drugs, end to Zantac fallout
British pharmaceutical group GSK reported Wednesday a sharp rise in annual net profit, boosted by strong sales of HIV, respiratory and cancer treatments as it recovered from costly US lawsuits over its Zantac heartburn treatment.
Luke Miels has to replace several sales agents. Vaccine fatigue creates new problems for the pharmaceutical company GSK. Analysts speculate about a savings program.
·Düsseldorf, Germany
Read Full ArticleCoverage Details
Total News Sources76
Leaning Left11Leaning Right5Center24Last UpdatedBias Distribution60% Center
Bias Distribution
- 60% of the sources are Center
60% Center
L 28%
C 60%
12%
Factuality
To view factuality data please Upgrade to Premium
